3 Lucrative Stocks That Raise Our Concerns

Profitability Isn’t Everything

While turning a profit is important, it doesn’t always ensure a company’s future success. Businesses that become complacent with their profit margins may fall behind as competition grows fiercer—echoing Jeff Bezos’s sentiment: “Your margin is my opportunity.”

It’s clear that not all profitable companies are equally strong. That’s why StockStory was created: to help you identify the companies that truly stand out. Below, we highlight three profitable businesses that don’t quite make the grade, along with some alternatives worth considering.

Q2 Holdings (QTWO)

Trailing 12-Month GAAP Operating Margin: 5%

Q2 Holdings (NYSE:QTWO) delivers cloud-based digital banking solutions, supporting around 25 million account holders nationwide. Their platform enables financial institutions, fintech firms, and alternative lenders to offer modern digital banking experiences.

Concerns About QTWO

• Annual recurring revenue only grew by 11.2% last year, indicating difficulties in attracting and keeping long-term clients.
• Projected sales growth of 10.3% for the coming year suggests a slowdown compared to the previous two-year trend.
• With a gross margin of just 54.1%, QTWO lags behind its peers, limiting resources available for marketing and research & development.

QTWO currently trades at $51.27 per share, equating to a forward price-to-sales ratio of 4.1.

ANI Pharmaceuticals (ANIP)

Trailing 12-Month GAAP Operating Margin: 12.6%

ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets a broad range of 116 branded and generic prescription drugs, with a growing emphasis on rare disease therapies.

Why We’re Cautious About ANIP

• With revenues of $883.4 million, the company has less leverage over fixed costs and fewer distribution options compared to larger competitors.
• Operational efficiency has declined, as shown by a 1.6 percentage point drop in adjusted operating margin over the past two years.
• Negative returns on capital indicate unsuccessful expansion efforts by management.

ANI Pharmaceuticals is priced at $75.98 per share, reflecting a forward P/E ratio of 8.3.

BNY (BK)

Trailing 12-Month GAAP Operating Margin: 36.1%

Founded in 1784 by Alexander Hamilton, BNY (NYSE:BK) is a global financial powerhouse offering asset servicing, wealth management, and investment solutions to institutions, corporations, and affluent individuals.

Why BK May Not Stand Out

• Its large scale can hinder growth, as seen in its below-average annual revenue increase of 4.7% over the past five years compared to smaller rivals.
• Tangible book value per share has only grown 3.2% annually in the last five years, lagging behind industry peers due to the challenges of growing a sizable balance sheet.
• Returns on equity are lower than average, suggesting management has struggled to find attractive investment opportunities.

BNY shares are trading at $115.43, with a forward P/E of 13.8.

Top Stocks for Every Market Environment

Don’t Miss: This Week’s Top 6 Stock Picks
The current market is quickly distinguishing high-quality stocks from overpriced ones, with AI-driven shifts impacting entire sectors unexpectedly. In such a fast-moving environment, you need more than just a list of solid companies.

Our AI platform identified Palantir before its 1,662% surge, AppLovin ahead of its 753% rally, and Nvidia before its 1,178% climb. Each week, it highlights six new stocks that meet our rigorous criteria.

Our 2020 picks included now-household names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Exlservice, which delivered a 354% five-year return.